{ "@context": "https://schema.org", "@graph": [ { "@type": "LegalCase", "@id": "case-9732", "postId": 9732, "name": "The Ensign Group, Inc.", "description": "Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Ensign Group To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in The Ensign Group between February 10, 2022 and June 18, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Ensign Group, Inc. (\u201cThe Ensign Group\u201d or the \u201cCompany\u201d) (NASDAQ: ENSG) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Ensign’s business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (2) Ensign’s abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (3) Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients; (4) Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (5) Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents; (6) Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; (7) Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model; and (8) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. Lead Plaintiff Deadline: December 7, 2026 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.", "identifier": "ENSG", "legal": { "court": "Central District of California", "jurisdiction": "Federal (United States), federal securities laws" }, "classPeriod": { "start": "02/10/2022", "end": "06/18/2026" }, "leadPlaintiffDeadline": "12/07/2026", "caseStatus": { "name": "", "slug": "" }, "practiceArea": { "name": "Securities Litigation", "slug": "securities-litigation" }, "url": "https://faruqilaw.com/case/the-ensign-group-inc/", "canonicalUrl": "https://faruqilaw.com/case/the-ensign-group-inc/", "datePublished": "2026-10-12T18:26:07+00:00", "dateModified": "2026-10-12T18:26:07+00:00", "associatedOrganization": { "@id": "case-9732-org" }, "legalService": { "@id": "case-9732-legalservice" }, "hasPart": [ { "@id": "case-9732-faq" }, { "@id": "case-9732-press-list" } ], "legalRepresentation": [ { "@id": "case-9732-attorney-516" }, { "@id": "case-9732-attorney-506" } ] }, { "@type": "Organization", "@id": "case-9732-org", "name": "The Ensign Group, Inc.", "identifier": "ENSG", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "url": "https://www.ensigngroup.net" }, { "@type": "LegalService", "@id": "case-9732-legalservice", "name": "Faruqi & Faruqi, LLP", "url": "https://faruqilaw.com/", "telephone": "+1-212-983-9330", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "address": { "@type": "PostalAddress", "streetAddress": "685 3rd Ave 26th Floor", "addressLocality": "New York", "postalCode": "10017", "addressRegion": "NY", "addressCountry": "US" }, "sameAs": [ "https://faruqilaw.com/", "https://maps.google.com/?cid=3247549158190754383" ] }, { "@type": "Person", "@id": "case-9732-attorney-516", "name": "James M. Wilson, Jr.", "worksFor": { "@id": "case-9732-legalservice" } }, { "@type": "Person", "@id": "case-9732-attorney-506", "name": "Robert W. Killorin", "worksFor": { "@id": "case-9732-legalservice" } }, { "@type": "FAQPage", "@id": "case-9732-faq", "mainEntity": [ { "@type": "Question", "name": "What is the Ensign Group securities class action lawsuit about?", "acceptedAnswer": { "@type": "Answer", "text": "The Ensign Group securities class action alleges that the company made materially false and misleading statements about its business, operations, and prospects during the class period from February 10, 2022 to June 18, 2026. The lawsuit alleges that Ensign's business model allegedly depended on the systematic neglect of elderly residents and that the company concealed significant reputational and legal exposure from investors." } }, { "@type": "Question", "name": "Who is eligible to join the Ensign Group class action lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "Investors who purchased or acquired The Ensign Group (NASDAQ: ENSG) securities between February 10, 2022 and June 18, 2026 may be eligible to participate in the class action. The lead plaintiff deadline is December 7, 2026, so affected investors should act promptly to understand their rights." } }, { "@type": "Question", "name": "What does the Ensign Group lawsuit allege about patient care at its facilities?", "acceptedAnswer": { "@type": "Answer", "text": "The lawsuit alleges that Ensign's business model depends on the widespread neglect of elderly residents, including those requiring high levels of care. Specifically, the complaint alleges that residents were denied adequate food, medical attention, and basic toiletries, and that the company allegedly failed to respond to residents in clear distress, resulting in deaths." } }, { "@type": "Question", "name": "Did the Ensign Group allegedly commit Medicare and Medicaid fraud?", "acceptedAnswer": { "@type": "Answer", "text": "The lawsuit alleges that Ensign defrauded Medicare and Medicaid by accepting federal funds designated to care for high-needs patients while allegedly neglecting those same patients. The complaint further alleges that Ensign falsified records showing the number of hours Certified Nursing Assistants spent with residents." } }, { "@type": "Question", "name": "What does the Ensign Group lawsuit allege about nursing staff records?", "acceptedAnswer": { "@type": "Answer", "text": "The lawsuit alleges that Ensign falsified the number of hours that Certified Nursing Assistants spent with residents at its facilities. This alleged falsification of staffing records is presented as part of a broader pattern of misrepresentation about the quality and nature of care provided to residents." } }, { "@type": "Question", "name": "What is the lead plaintiff deadline for the Ensign Group securities lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "The deadline to apply to serve as lead plaintiff in the Ensign Group securities class action is December 7, 2026. The case has been filed in the Central District of California, and investors who believe they have suffered losses may wish to consult with counsel before this deadline." } }, { "@type": "Question", "name": "What did the Ensign Group allegedly do to cover up neglect at its facilities?", "acceptedAnswer": { "@type": "Answer", "text": "The lawsuit alleges that Ensign used self-reporting measures as a mechanism to conceal systematic patient neglect across its facilities. The complaint also alleges that the company engaged in an illegal scheme involving the rental of licenses from Administrators who were not actually present at or managing its facilities." } }, { "@type": "Question", "name": "How did Ensign Group allegedly mislead investors about its business risks?", "acceptedAnswer": { "@type": "Answer", "text": "How did Ensign Group allegedly mislead investors about its business risks?" } } ] }, { "@type": "NewsArticle", "@id": "case-9732-press-1", "headline": "Ensign Group (ENSG) Rebounds After June Short-Seller Report Hit Shares", "url": "https://news.alphastreet.com/ensign-group-ensg-rebounds-after-june-short-seller-report-hit-shares/", "datePublished": "2026-09-22" }, { "@type": "NewsArticle", "@id": "case-9732-press-2", "headline": "Ensign Group shares drop after Muddy Waters raises compliance concerns", "url": "https://seekingalpha.com/news/4602723-ensign-group-shares-drop-after-muddy-waters-raises-compliance-concerns", "datePublished": "2026-06-11" }, { "@type": "NewsArticle", "@id": "case-9732-press-3", "headline": "Ensign Group shares drop after short seller alleges compliance issues", "url": "https://www.investing.com/news/stock-market-news/ensign-group-shares-drop-after-short-seller-alleges-compliance-issues-93CH-4738095", "datePublished": "2026-06-11" }, { "@type": "NewsArticle", "@id": "case-9732-press-4", "headline": "Ensign Group (ENSG) Sees 4% Drop Following Short Report", "url": "https://www.gurufocus.com/news/8912528/ensign-group-ensg-sees-4-drop-following-short-report", "datePublished": "2026-06-11" }, { "@type": "NewsArticle", "@id": "case-9732-press-5", "headline": "Ensign (ENSG) Faces Short Selling Amid Allegations of Mismanagement", "url": "https://www.gurufocus.com/news/8912526/ensign-ensg-faces-short-selling-amid-allegations-of-mismanagement", "datePublished": "2026-06-11" }, { "@type": "NewsArticle", "@id": "case-9732-press-6", "headline": "Ensign Group slides as short-seller report sparks investor concern", "url": "https://www.quiverquant.com/news/Ensign+Group+slides+as+short-seller+report+sparks+investor+concern", "datePublished": "2026-06-08" }, { "@type": "NewsArticle", "@id": "case-9732-press-7", "headline": "The Ensign Group (ENSG) Q4 2021 Earnings Call Transcript", "url": "https://www.nasdaq.com/articles/the-ensign-group-ensg-q4-2021-earnings-call-transcript", "datePublished": "2022-02-10" }, { "@type": "ItemList", "@id": "case-9732-press-list", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "case-9732-press-1" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "case-9732-press-2" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "case-9732-press-3" } }, { "@type": "ListItem", "position": 4, "item": { "@id": "case-9732-press-4" } }, { "@type": "ListItem", "position": 5, "item": { "@id": "case-9732-press-5" } }, { "@type": "ListItem", "position": 6, "item": { "@id": "case-9732-press-6" } }, { "@type": "ListItem", "position": 7, "item": { "@id": "case-9732-press-7" } } ] } ] }

The Ensign Group, Inc.

The Ensign Group, Inc.

Join Action
Case Details
Ticker ENSG
Class Period 02/10/2022 - 06/18/2026
Lead Plaintiff Deadline 12/07/2026
Days Left to Seek Lead Plaintiff
56

If you are a The Ensign Group, Inc. investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Ensign Group To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in The Ensign Group between February 10, 2022 and June 18, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Ensign Group, Inc. (“The Ensign Group” or the “Company”) (NASDAQ: ENSG) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Ensign’s business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (2) Ensign’s abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (3) Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients; (4) Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (5) Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents; (6) Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; (7) Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model; and (8) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Lead Plaintiff Deadline: December 7, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Join Action
The Ensign Group, Inc.
1
1
1
1

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Counsel
James M. Wilson, Jr.
jwilson@faruqilaw.com
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin
rkillorin@faruqilaw.com
Phone (404) 847-0617
Fax (404) 506-9534
Office
New York
685 Third Avenue 26th Floor New York New York 10017
Phone (212) 983-9330
Fax (212) 983-9331

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771